Brief Summary
The Children's Oncology Group has established a research network, the Childhood Cancer Research Network (CCRN), to collect information about children with cancer and other conditions that are benign but involve abnormal cell growth in order to help doctors and scientists better understand childhood cancer. The CCRN's goal is to collect clinical information about every child diagnosed with cancer and similar conditions in the United States and Canada, to allow researchers to study patterns, characteristics, and causes of childhood cancer. The information can also help researchers study the causes of childhood cancer. To expand the CCRN, parents of children who have been diagnosed with cancer will be asked to provide information about themselves and their child for research purposes.
Brief Title
Enrollment on the Childhood Cancer Research Network (CCRN) of the Children's Oncology Group
Detailed Description
OBJECTIVES:
I. To obtain informed consent from parents of infants, children, adolescents, and young adults newly diagnosed with cancer (and their child when appropriate) to enter their names and certain information concerning their child into the Childhood Cancer Research Network and/or for permission to be contacted in the future to consider participating in future studies.
II. For children under the age of majority at the time of parental consent: Once the child reaches the age of majority, to obtain informed consent from that child to allow her/his name and other identifying information to continue to be available to the Childhood Cancer Research Network and/or to be possibly contacted in the future to consider participating in other studies.
OUTLINE:
Institutional membership in the Children's Oncology Group (COG) requires registration of all pediatric cancer patients seen at their site. This registration process includes all patients. In order to maximize the resource that a network would provide, it is necessary to have identifying information on a large proportion of the cases included within the network. Moreover, the resource would be further enhanced if informed consent from parents/patients was obtained to allow future contact regarding possible participation in non-therapeutic and prevention research.
I. To obtain informed consent from parents of infants, children, adolescents, and young adults newly diagnosed with cancer (and their child when appropriate) to enter their names and certain information concerning their child into the Childhood Cancer Research Network and/or for permission to be contacted in the future to consider participating in future studies.
II. For children under the age of majority at the time of parental consent: Once the child reaches the age of majority, to obtain informed consent from that child to allow her/his name and other identifying information to continue to be available to the Childhood Cancer Research Network and/or to be possibly contacted in the future to consider participating in other studies.
OUTLINE:
Institutional membership in the Children's Oncology Group (COG) requires registration of all pediatric cancer patients seen at their site. This registration process includes all patients. In order to maximize the resource that a network would provide, it is necessary to have identifying information on a large proportion of the cases included within the network. Moreover, the resource would be further enhanced if informed consent from parents/patients was obtained to allow future contact regarding possible participation in non-therapeutic and prevention research.
Categories
Completion Date
Completion Date Type
Estimated
Conditions
Pediatric Cancer
Leukemia
Sarcoma
Brain Tumors
Eligibility Criteria
* All patients, diagnosed with a primary malignancy since the date the initial IRB approval was received for this study with any of the following diagnoses are eligible:
* All cancer cases with an ICD-O histologic behavior code of two "2" (carcinoma in situ) or three "3" (malignant).
* All lesions of the central nervous system regardless of behavior, i.e., benign, borderline or malignant.
* The benign/borderline conditions which will be reportable by agreement shall include:
* Mesoblastic nephroma.
* All teratomas, regardless of locations.
* Myeloproliferative disease
* Langerhans Cell histiocytosis
* Patients with a secondary malignancy may be eligible provided they also meet the criteria in the above. These patients need to be enrolled using their primary diagnosis.
* Participants 0 through 21 years of age are eligible; irrespective of eligibility for other COG studies.
* Participant must be resident of the United States, Canada or Mexico.
* All cancer cases with an ICD-O histologic behavior code of two "2" (carcinoma in situ) or three "3" (malignant).
* All lesions of the central nervous system regardless of behavior, i.e., benign, borderline or malignant.
* The benign/borderline conditions which will be reportable by agreement shall include:
* Mesoblastic nephroma.
* All teratomas, regardless of locations.
* Myeloproliferative disease
* Langerhans Cell histiocytosis
* Patients with a secondary malignancy may be eligible provided they also meet the criteria in the above. These patients need to be enrolled using their primary diagnosis.
* Participants 0 through 21 years of age are eligible; irrespective of eligibility for other COG studies.
* Participant must be resident of the United States, Canada or Mexico.
Inclusion Criteria
* All patients, diagnosed with a primary malignancy since the date the initial IRB approval was received for this study with any of the following diagnoses are eligible:
* All cancer cases with an ICD-O histologic behavior code of two "2" (carcinoma in situ) or three "3" (malignant).
* All lesions of the central nervous system regardless of behavior, i.e., benign, borderline or malignant.
* The benign/borderline conditions which will be reportable by agreement shall include:
* Mesoblastic nephroma.
* All teratomas, regardless of locations.
* Myeloproliferative disease
* Langerhans Cell histiocytosis
* Patients with a secondary malignancy may be eligible provided they also meet the criteria in the above. These patients need to be enrolled using their primary diagnosis.
* Participants 0 through 21 years of age are eligible; irrespective of eligibility for other COG studies.
* Participant must be resident of the United States, Canada or Mexico.
* All cancer cases with an ICD-O histologic behavior code of two "2" (carcinoma in situ) or three "3" (malignant).
* All lesions of the central nervous system regardless of behavior, i.e., benign, borderline or malignant.
* The benign/borderline conditions which will be reportable by agreement shall include:
* Mesoblastic nephroma.
* All teratomas, regardless of locations.
* Myeloproliferative disease
* Langerhans Cell histiocytosis
* Patients with a secondary malignancy may be eligible provided they also meet the criteria in the above. These patients need to be enrolled using their primary diagnosis.
* Participants 0 through 21 years of age are eligible; irrespective of eligibility for other COG studies.
* Participant must be resident of the United States, Canada or Mexico.
Gender
All
Gender Based
false
Keywords
Children's Oncology Group
Pediatric Oncology
Pediatric Cancer
Registration
Leukemia
Brain Tumor
Sarcoma
Healthy Volunteers
No
Last Update Post Date
Last Update Post Date Type
Estimated
Last Update Submit Date
Maximum Age
21 Years
NCT Id
NCT01117168
Org Class
Network
Org Full Name
Children's Oncology Group
Org Study Id
ACCRN07
Overall Status
Active, not recruiting
Primary Completion Date
Primary Completion Date Type
Estimated
Official Title
Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN)
Primary Outcomes
Outcome Measure
To collect information on children with cancer
Outcome Time Frame
After initial diagnosis
Secondary Ids
Secondary Id
10-C-0111
Secondary Id
100111
Secondary Outcomes
Outcome Time Frame
At enrollment and at age of majority
Outcome Measure
To obtain consent to contact in the future for participation in future clinical trials
Start Date
Status Verified Date
First Post Date
First Post Date Type
Estimated
First Submit Date
First Submit QC Date
Study Population
Pediatric and adolescent patients diagnosed with cancer
Std Ages
Child
Adult
Maximum Age Number (converted to Years and rounded down)
21
Minimum Age Number (converted to Years and rounded down)
0
Investigators
Investigator Type
Principal Investigator
Investigator Name
Lisa Gennarini
Investigator Email
lfigueir@montefiore.org
Investigator Phone
Categories Mesh Debug
Cancer --- NEOPLASMS
Cancer --- LEUKEMIA
Blood & Bone Marrow Cancers --- LEUKEMIA
Cancer --- SARCOMA
Sarcomas --- SARCOMA
Brain, Spine & Nerve Cancers --- BRAIN NEOPLASMS
Blood Disorders --- HEMATOLOGIC DISEASES
Blood & Bone Marrow Cancers --- HEMATOLOGIC DISEASES
Brain, Spine & Nerve Cancers --- NEOPLASMS, CONNECTIVE AND SOFT TISSUE
Brain, Spine & Nerve Cancers --- CENTRAL NERVOUS SYSTEM NEOPLASMS
Brain, Spine & Nerve Cancers --- NERVOUS SYSTEM NEOPLASMS
Cancer --- NEOPLASMS BY SITE
Alzheimer's --- BRAIN DISEASES
Brain, Spinal Cord & Nervous System --- BRAIN DISEASES
Brain, Spine & Nerve Cancers --- BRAIN DISEASES
Alzheimer's --- CENTRAL NERVOUS SYSTEM DISEASES
Brain, Spinal Cord & Nervous System --- CENTRAL NERVOUS SYSTEM DISEASES
Brain, Spine & Nerve Cancers --- CENTRAL NERVOUS SYSTEM DISEASES
Brain, Spinal Cord & Nervous System --- NERVOUS SYSTEM DISEASES
Brain, Spine & Nerve Cancers --- NERVOUS SYSTEM DISEASES
MeSH Terms
NEOPLASMS
LEUKEMIA
SARCOMA
BRAIN NEOPLASMS
NEOPLASMS BY HISTOLOGIC TYPE
HEMATOLOGIC DISEASES
HEMIC AND LYMPHATIC DISEASES
NEOPLASMS, CONNECTIVE AND SOFT TISSUE
CENTRAL NERVOUS SYSTEM NEOPLASMS
NERVOUS SYSTEM NEOPLASMS
NEOPLASMS BY SITE
BRAIN DISEASES
CENTRAL NERVOUS SYSTEM DISEASES
NERVOUS SYSTEM DISEASES